Partially observable Markov decision model for the treatment of early Prostate Cancer

OPSEARCH

Volumn 47, Issue 2, 2010, Pages 105-117

  Goulionis, John E ^a   Koutsiumaris, B K ^a  

^a UNIVERSITY OF PIRAEUS   (Greece)

Author keywords

Health policy; Medical decision making; Partially observable Markov processes; Stochastic optimal control

Indexed keywords

EID: 79954426905     PISSN: 00303887     EISSN: 09750320     Source Type: Journal    
DOI: 10.1007/s12597-010-0015-0     Document Type: Article

References (29)

1. Sondik, E.: The optimal control of POMDPs over the infinite horizon. Oper Res 26, 282-304 (1978)
2. Papadimitriou, G.H., Tsitsiklis, J.N.: The complexity of Markov decision processes. Math Oper Res 12, 441-450 (1987)
3. Albertsen, P.C., Fryback, D.G., Storer, B.E., Kolon, T.F., Fine, J.: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274, 626-631 (1995)
4. Walsh, P.C., Brooks, J.D.: The Swedish prostate cancer paradox [Editorial]. JAMA 277, 497-498 (1997) (Pubitemid 27074336)
5. American Academy of Family Physicians. Summary of policy recommendations for periodic health examination. General population guidelines. AAFP Online, 19977:http://www.aafp.org/family/policy/camp/app-d.html.
6. Albertsen, P.C.: Early-stage prostate cancer. When is observation appropriate? Hematol Oncol Clin North Am 10, 611-625 (1996) (Pubitemid 26171133)
7. Halm, E.A., Fine, M.J., Marrie, T.J.: Time to clinical stability in patients hospitalized with community -acquired pneumonia. J Am Med Assoc 279(18), 1452-1457 (1998) (Pubitemid 28228202)
8. Partin, A.W., Carter, H.B.: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Am 23, 531-540 (1996) (Pubitemid 27000020)
9. U.S. Preventine Services Task Force: Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. Am J Prev Med 10, 187-193 (1994)
10. Von Eschenbach, A., Ho, R., Murphy, G.P., Cunningham, M., Lins, N.: American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 47, 261-264 (1997) (Pubitemid 27405931)
11. Goulionis, J.E., Stengos, Dimitrios I.: The partially observable Markov decision processes framework in Medical decision Making. Adv Appl Stat 9(2), 205-232 (2008)
12. Bertsekas, D.: Stochastic optimal control. The Discrete time case. Academic, New York (1998)
13. Ivy, J.S.A.: Maintenance model for breast cancer detection and treatment. Artif Inntell Med 18, 221-244 (2002)
14. Derman, C.: Finite State MDPs. Academic, New York (1970)
15. Stephenson, R.A., Smart, C.R., Mineau, G.P., James, B.C., Janerich, D.T., Dibble, R.L.: The fall in incidence of prostatic carcinoma. On the down side of a prostate specific antigen included peak in incidence-data from the Utah. Cancer Registry. Cancer 77, 1342-1348 (1996) (Pubitemid 26102334)
16. Pienta, K.J.: Epidemiology and etiology of prostate cancer. In: Raghaven, D., et al. (eds.) Principles and practice of genitourinary oncology. Lippincott-Raven, Philadephia (1997)
17. Krongrad, A., Lai, H., Lamm, S.H., Lai, S.: Mortality in prostate cancer. J Urol 156, 1084-1091 (1996) (Pubitemid 26269834)
18. Silverberg E, Lubera JA.: A rewiew of the American Cancer Society: estimates of cancer cases and deaths. CA Cancer J Clin, 36-39 (1986)
19. Consensus conference.: The management of clinically localized prostate cancer. JAMA 258, 2727-30 (1987)
20. Arcangeli, C.G., Ornstein, D.K., Keetch, D.W., Andriole, G.L.: Prostate-specific antigen as a screening test for prostate cancer. Urol Clin North Am 24, 299-314 (1997)
21. Carter, H.B., Epstein, J.I., Chan, D.W., Fozard, J.L., Pearson, J.D.: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277, 1456-1460 (1997) (Pubitemid 27208888)
22. Shipley, W.U., Zietman, A.L., Hanks, G.E., Goen, J.J., Caplan, R.J., Won, M., et al.: Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 152(5Pt2), 1799-1805 (1994) (Pubitemid 24322632)
23. Keetch, D.W., Rice, J.P., Suarez, B.K., Catalona, W.J.: Familial aspects of prostate cancer: a case control study. J Urol 154, 2100-2102 (1995)
24. Woolf, S.H.: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 33, 1401-1405 (1995)
25. Lubke, W.L., Optenberg, S.A.: Thompson I.M. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst 86, 1790-1792 (1994) (Pubitemid 24373456)
26. Striebel, C.T.: Sufficient statistics in the optimal control of stochastic systems. J Math Anal Appl 12, 576-592 (1965)
27. Aström, J.: Optimal control of Markov processes with incomplete state information. J. Math. Anal. Appl 10, 174-205 (1965)
28. Goulionis, J.E., Benos, V.K.: Optimal control limit strategies, using the partially observable Markov decision processes. Adv Appl Stat 7(3), 357-388 (2007)
29. Denardo, E.V.: Contraction mapping in the theory underlying dynamic programming. Siam Reviews 9, 165-177 (1967)